SANUWAVE Health to Present at the Newport Coast Securities 2014 National Sales & Equity Conference

SANUWAVE Health to Present at the Newport Coast Securities 2014 National Sales
& Equity Conference

ALPHARETTA, Ga., June 10, 2014 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc.
(OTCQB:SNWV) announced the Company will present at the Newport Coast
Securities 2014 National Sales & Equity Conference on Friday, June 13, at the
W New York Hotel in New York City.

Kevin Richardson, SANUWAVE's Chairman of the board of directors, will present
a corporate overview at 11:30 AM ET on Friday, June 13, 2014.

Company management will be available for one-on-one meetings with investors
participating in the conference. For those who would like to schedule an
appointment with SANUWAVE's management, please contact DC Consulting by phone,
(407) 792-3333, or email investorinfo@dcconsultingllc.com.

The annual Newport Coast Securities conference will feature presentations from
a carefully selected group of micro-cap and small cap growth companies. The
event is designed to provide investors and Newport Coast Securities advisors
with a unique opportunity to gain insight into emerging growth companies and
world class alternative investment opportunities. For more information, please
contact conferences@ncsecurities.com, or to register go to
www.regonline.com/newportcoastsecuritiesinc2014nationalsalesequityco.

About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company
initially focused on the development and commercialization of patented
noninvasive, biological response activating devices for the repair and
regeneration of skin, musculoskeletal tissue and vascular structures.
SANUWAVE's portfolio of regenerative medicine products and product candidates
activate biologic signaling and angiogenic responses, producing new
vascularization and microcirculatory improvement, which helps restore the
body's normal healing processes and regeneration. SANUWAVE applies its
patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic
and cardiac conditions. Its lead product candidate for the global wound care
market, dermaPACE^®, is CE Marked throughout Europe and has device license
approval for the treatment of the skin and subcutaneous soft tissue in Canada,
Australia and New Zealand.In the U.S., dermaPACE is currently under the FDA's
Premarket Approval (PMA) review process for the treatment of diabetic foot
ulcers.SANUWAVE researches, designs, manufactures, markets and services its
products worldwide, and believes it has demonstrated that its technology is
safe and effective in stimulating healing in chronic conditions of the foot
(plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S.
Class III PMA approved OssaTron^® device, as well as stimulating bone and
chronic tendonitis regeneration in the musculoskeletal environment through the
utilization of its OssaTron, Evotron^® and orthoPACE^® devices in Europe, Asia
and Asia/Pacific.In addition, there are license/partnership opportunities for
SANUWAVE's shock wave technology for non-medical uses, including energy,
water, food and industrial markets.

Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995, such as statements
relating to financial results and plans for future business development
activities, and are thus prospective. Forward-looking statements include all
statements that are not statements of historical fact regarding intent, belief
or current expectations of the Company, its directors or its officers.
Investors are cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and uncertainties, many of
which are beyond the Company's ability to control. Actual results may differ
materially from those projected in the forward-looking statements. Among the
key risks, assumptions and factors that may affect operating results,
performance and financial condition are risks associated with the regulatory
approval and marketing of the Company's product candidates and products,
unproven pre-clinical and clinical development activities, regulatory
oversight, the Company's ability to manage its capital resource issues,
competition, and the other factors discussed in detail in the Company's
periodic filings with the Securities and Exchange Commission. The Company
undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit www.sanuwave.com.

CONTACT: DC Consulting, LLC
         407-792-3333
         investorinfo@dcconsultingllc.com
        
         Investor Relations
         RedChip Companies, Inc.
         Mike Bowdoin, Vice President
         800-733-2447, ext. 110
         mike@redchip.com

SANUWAVE Health, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.